Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Thanks Johnny - B good ! Having been around this beauty so long, I have to resist that "Grand Challenge' feeling . . . . . Whilst some Posters say that their main hopes rest in the Scancell's other projects, I myself continue to have great faith in the almost unbelievable scale of the potential for 'Covidity''. Let's hope the data is good.
What an amazing Lady is our Prof. !! Thanks again and what a good job the 'translator' did. ATB
Very interesting. Good find Johnny.
Thanks for that JohnnyB. Yes for me that's the bit that stands out. IMO, the later AGM Is hopefully to do with something Important to Sclp. AIMO.
The edited highlight of the tweet is:-
"We are about to announce a vaccine program that includes other parts of the SARS-CoV-2 virus, not just the spike protein but a broader antigenic repertoire. '
Why is this important? "All the vaccines we have at the moment use this spike protein but there are many mutations in that part of the virus, so we need to develop vaccines that are not susceptible to small changes in the spike protein or receptor binding domain: a different conceptual approach is needed in order to to anticipate rather than chase the virus ".
It is in Italian so I have translated it on google
https://twitter.com/CEPIvaccines/status/1451955132036493312?ref_src=twsrc%5Egoogle%7Ctwcamp%5Eserp%7Ctwgr%5Etweet
Ongoing studies concern the new variants, but also simpler administration mechanisms, for example via the nose, and without refrigeration.
“This is not the time to rest on our laurels. Now that we are producing large quantities of vaccines globally - we will have produced 12 billion by the end of the year - and slowly starting to straighten the inequalities in their distribution, there are challenges that point to the need to invest in research. The objectives: to optimize the vaccines we have, but also to develop second and third generation vaccines that are both resistant to variants and easier to administer and for example do not require refrigeration. In short, we must invest to stay one step ahead of the virus ».
The American Richard Hatchett speaks, formerly in the White House under the presidency of George W. Bush and then that of Barack Obama, now CEO of CEPI (Coalition of Epidemic Preparedness Innovation), a partnership of public and private subjects launched in Davos in 2017, which co-manages Covax with the WHO and with Gavi, and is supported by the G20 on the theme of preparing for the epidemics of the future. CEPI, which helped fund the initial development of COVID-19 vaccines, aims to raise $ 3.5 billion for global epidemic and pandemic risk reduction through vaccine development and equitable distribution.
Where are we in the development of next generation vaccines? «CEPI has opened to proposals for a vaccine that protects against betacoronaviruses, that is, not only from SARS-CoV-2 but from SARS, MERS and other coronaviruses that will emerge in the future. We are going to review the proposals received and decide which ones we want to support. CEPI has already invested in some second generation vaccines: we will not have them in 2021, if we are lucky in 2022. In addition to dealing with the new variants, there is the goal of developing vaccines that are simpler to administer, which do not require rigorous cold chain or which involve a single dose. With the University of Hong Kong, we invested in a nasal vaccine, without a needle, which can block the transmission of the virus through mucosal immunity, protecting the upper airways. This is just an idea. We are about to announce a vaccine program that includes other parts of the SARS-CoV-2 virus, not just the spike protein but a broader antigenic repertoire. '
Why is this important? "All the vaccines we have at the moment use this spike protein but there are many mutations in that part of the virus, so we need to develop vaccines that are not susceptible to small changes in the spike protein or receptor binding domain: a different conceptual approach is needed in order to to anticipate rather than chase the virus ".
CONTINUED IN NEXT MESSAGE